Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Metabolic dysfunction–associated steatohepatitis (MASH) represents a progressive form of steatotic liver disease which increases the risk for fibrosis and advanced liver disease. The accumulation of discrete species of bioactive lipids has been postulated to activate signaling pathways that promote inflammation and fibrosis. However, the key pathogenic lipid species is a matter of debate. We explored candidates using various dietary, molecular, and genetic models. Mice fed a choline-deficient L-amino acid–defined high-fat diet (CDAHFD) developed steatohepatitis and manifested early markers of liver fibrosis associated with increased cholesterol content in liver lipid droplets within 5 d without any changes in total liver cholesterol content. Treating mice with antisense oligonucleotides against Coenzyme A synthase ( Coasy ) or treatment with bempedoic acid or atorvastatin decreased liver lipid droplet cholesterol content and prevented CDAHFD-induced MASH and the fibrotic response. All these salutary effects were abrogated with dietary cholesterol supplementation. Analysis of human liver samples demonstrated that cholesterol in liver lipid droplets was increased in humans with MASH and liver fibrosis and was higher in PNPLA3 I148M (variants rs738409) than in HSD17B13 variants (rs72613567). Together, these data identify cholesterol in liver lipid droplets as a critical mediator of MASH and demonstrate that Coenzyme A synthase knockdown and bempedoic acid are therapeutic approaches to reduce liver lipid droplet cholesterol content and thereby prevent the development of MASH and liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“BA treatment also reduced TG and total cholesterol content in liver LDs.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [146]
In the citing paper
“BA is a prodrug that requires activation by a liver-specific enzyme, very long-chain ACSL1.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [146]
In the citing paper
“Notably, bempedoic acid (BA) works as an ACLY inhibitor, which is clinically used as a plasma cholesterol-lowering drug.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [146]
In the citing paper
“BA is a particularly important therapeutic agent, as it simultaneously inhibits cholesterol synthesis and DNL, making it potentially effective for treating MASH while also improving major CV outcomes [146-148].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [146]
In the citing paper
“It effectively lowers LDL-cholesterol and reduces CV risk without muscle-related side effects.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput
Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S., & Ralser, M. (2020) · Nature Methods · doi:10.1038/s41592-019-0638-x · Cited by 3,343
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citationvan der Veen, J. N., Kennelly, J. P., Wan, S., Vance, J. E., Vance, D. E., & Jacobs, R. L. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.04.006 · Cited by 1,514
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032
Self-citationLipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847 · cited 1×
“Instead, other lipid species, such as fatty acids, cholesterol, lysophosphatidic acid, lysophosphatidylcholine, and ceramides, have all been implicated in causing hepatic inflammation and fibrosis ( 4 – 7 ).”
A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827 · cited 2×
“The hydroxysteroid 17 - beta dehydrogenase 13 (HSD17B13) splice site variant (rs72613567) decreases the risk of MASH (29).”
Morino, K. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25151 · Cited by 811
Self-citationSafety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807 · cited 1×
“Bempedoic acid works as an ATP - citrate lyase inhibitor, which is clinically used as a plasma cholesterol - lowering drug (21).”
Xiong, X., Kuang, H., Ansari, S., Liu, T., Gong, J., Wang, S., Zhao, X.-Y., Ji, Y., Li, C., Guo, L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.028 · Cited by 784
Lysosomal membrane permeabilization and cell death
Wang, F., Gómez‐Sintes, R., & Boya, P. (2018) · Traffic · doi:10.1111/tra.12613 · Cited by 776
Li, Z., Agellon, L. B., Allen, T. M., Umeda, M., Jewell, L., Mason, A., & Vance, D. E. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.03.007 · Cited by 752
Remmerie, A., Martens, L., Thoné, T., Castoldi, A., Seurinck, R., Pavie, B., Roels, J., Vanneste, B., De Prijck, S., Vanhockerhout, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.004 · Cited by 592 · cited 1×
“Resident Kupffer cells are replaced by distinct subsets of bone marrow derived macrophages ( 16 ).”
An improved mouse model that rapidly develops fibrosis in non‐alcoholic steatohepatitis
Matsumoto, M., Hada, N., Sakamaki, Y., Uno, A., Shiga, T., Tanaka, C., Ito, T., Katsume, A., & Sudoh, M. (2013) · International Journal of Experimental Pathology · doi:10.1111/iep.12008 · Cited by 523 · cited 1×
“The choline - deficient L - amino acid–defined high - fat diet (CDAHFD) model has been advanced as a mouse model that mirrors the pathological progression of MASLD (steatosis ➾ hepatitis ➾ fibrosis) ( 8 , 9 ).”
Condensed complexes of cholesterol and phospholipids
McConnell, H. M., & Radhakrishnan, A. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(03)00015-4 · Cited by 384
Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation
Fabre, T., Barron, A. M. S., Christensen, S. M., Asano, S., Bound, K., Lech, M. P., Wadsworth, M. H., Chen, X., Wang, C., Wang, J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add8945 · Cited by 355
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353 · cited 1×
“Metabolic dysfunction–associated steatosis liver disease (MASLD) is the predominant chronic liver disease in the world, affecting approximately 25% of the global population ( 1 , 2 ).”
Pirazzi, C., Adiels, M., Burza, M. A., Mancina, R. M., Levin, M., Ståhlman, M., Taskinen, M.-R., Orho-Melander, M., Perman, J., Pujia, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.030 · Cited by 305
Apostolopoulou, M., Gordillo, R., Koliaki, C., Gancheva, S., Jelenik, T., De Filippo, E., Herder, C., Markgraf, D., Jankowiak, F., Esposito, I., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1318 · Cited by 284
Self-citationAccumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis
BasuRay, S., Wang, Y., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901974116 · Cited by 284
Emerging Roles for the Lysosome in Lipid Metabolism
Thelen, A. M., & Zoncu, R. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.07.006 · Cited by 266
PNPLA3, CGI‐58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice
Wang, Y., Kory, N., BasuRay, S., Cohen, J. C., & Hobbs, H. H. (2019) · Hepatology · doi:10.1002/hep.30583 · Cited by 219
Chen, Y., Du, X., Kuppa, A., Feitosa, M. F., Bielak, L. F., O’Connell, J. R., Musani, S. K., Guo, X., Kahali, B., Chen, V. L., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01497-6 · Cited by 215
Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
Horn, C. L., Morales., A. L., Savard, C., Farrell, G. C., & Ioannou, G. N. (2022) · Hepatology Communications · doi:10.1002/hep4.1801 · Cited by 214
Itoh, M., Kato, H., Suganami, T., Konuma, K., Marumoto, Y., Terai, S., Sakugawa, H., Kanai, S., Hamaguchi, M., Fukaishi, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082163 · Cited by 211 · cited 1×
“Activated fibroblasts and collagen deposition are observed around crown - like structures, and the number of crown - like structures positively correlates with the fibrosis area ( 42 ).”
Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis
Wang, X., Cai, B., Yang, X., Sonubi, O. O., Zheng, Z., Ramakrishnan, R., Shi, H., Valenti, L., Pajvani, U. B., Sandhu, J., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.03.010 · Cited by 204
A researcher’s guide to preclinical mouse NASH models
Gallage, S., Avila, J. E. B., Ramadori, P., Focaccia, E., Rahbari, M., Ali, A., Malek, N. P., Anstee, Q. M., & Heikenwalder, M. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00700-y · Cited by 203
Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
Morrow, M. R., Batchuluun, B., Wu, J., Ahmadi, E., Leroux, J. M., Mohammadi-Shemirani, P., Desjardins, E. M., Wang, Z., Tsakiridis, E. E., Lavoie, D. C. T., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.004 · Cited by 199 · cited 2×
“In addition recent studies have also demonstrated that bempedoic acid reduces the development of liver inflammation in mouse models of MASH ( 22 , 45 ).”
Zernecke, A., Erhard, F., Weinberger, T., Schulz, C., Ley, K., Saliba, A.-E., & Cochain, C. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac161 · Cited by 191
Hepatic lipid droplet homeostasis and fatty liver disease
Seebacher, F., Zeigerer, A., Kory, N., & Krahmer, N. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.04.011 · Cited by 190
Farrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178
A Membrane-Bound Diacylglycerol Species Induces PKCϵ-Mediated Hepatic Insulin Resistance
Lyu, K., Zhang, Y., Zhang, D., Kahn, M., ter Horst, K. W., Rodrigues, M. R. S., Gaspar, R. C., Hirabara, S. M., Luukkonen, P. K., Lee, S., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.001 · Cited by 170
Self-citationCarlsson, B., Lindén, D., Brolén, G., Liljeblad, M., Bjursell, M., Romeo, S., & Loomba, R. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15738 · Cited by 169
Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids
Luukkonen, P. K., Nick, A., Hölttä-Vuori, M., Thiele, C., Isokuortti, E., Lallukka-Brück, S., Zhou, Y., Hakkarainen, A., Lundbom, N., Peltonen, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127902 · Cited by 161
Luukkonen, P. K., Zhou, Y., Haridas, P. A. N., Dwivedi, O. P., Hyötyläinen, T., Ali, A., Juuti, A., Leivonen, M., Tukiainen, T., Ahonen, L. L., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.014 · Cited by 158
Bogan, J. S., McKee, A. E., & Lodish, H. F. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.14.4785-4806.2001 · Cited by 152
Mechanisms by which adiponectin reverses high fat diet-induced insulin resistance in mice
Li, X., Zhang, D., Vatner, D. F., Goedeke, L., Hirabara, S. M., Zhang, Y., Perry, R. J., & Shulman, G. I. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922169117 · Cited by 150
Self-citationThe therapeutic potential of galectin-3 inhibition in fibrotic disease
Slack, R. J., Mills, R., & Mackinnon, A. C. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105881 · Cited by 136
Lee, H.-Y., Birkenfeld, A. L., Jornayvaz, F. R., Jurczak, M. J., Kanda, S., Popov, V., Frederick, D. W., Zhang, D., Guigni, B., Bharadwaj, K. G., et al. (2011) · Hepatology · doi:10.1002/hep.24571 · Cited by 134
Self-citationEskridge, W., Cryer, D. R., Schattenberg, J. M., Gastaldelli, A., Malhi, H., Allen, A. M., Noureddin, M., & Sanyal, A. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196216 · Cited by 111
Zhou, X., Kim, S. U., Yip, T. C., Petta, S., Nakajima, A., Tsochatzis, E. A., Boursier, J., Bugianesi, E., Hagström, H., Chan, W., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-333074 · Cited by 108
Johnson, S. M., Bao, H., McMahon, C. E., Chen, Y., Burr, S. D., Anderson, A. M., Madeyski-Bengtson, K., Lindén, D., Han, X., & Liu, J. (2024) · Nature Communications · doi:10.1038/s41467-024-49224-x · Cited by 100
Luukkonen, P. K., Tukiainen, T., Juuti, A., Sammalkorpi, H., Haridas, P. A. N., Niemelä, O., Arola, J., Orho-Melander, M., Hakkarainen, A., Kovanen, P. T., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132158 · Cited by 99
Luukkonen, P. K., Porthan, K., Ahlholm, N., Rosqvist, F., Dufour, S., Zhang, X.-M., Lehtimäki, T. E., Seppänen, W., Orho-Melander, M., Hodson, L., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.008 · Cited by 97
Self-citationLipid-associated macrophages between aggravation and alleviation of metabolic diseases
Xu, R., Vujić, N., Bianco, V., Reinisch, I., Kratky, D., Krstic, J., & Prokesch, A. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.04.009 · Cited by 95
Itoh, M., Suganami, T., Kato, H., Kanai, S., Shirakawa, I., Sakai, T., Goto, T., Asakawa, M., Hidaka, I., Sakugawa, H., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92902 · Cited by 92
Ioannou, G. N., Landis, C. S., Jin, G., Haigh, W. G., Farrell, G. C., Kuver, R., Lee, S. P., & Savard, C. E. (2019) · Hepatology Communications · doi:10.1002/hep4.1348 · Cited by 92
Therapeutic opportunities for the treatment of NASH with genetically validated targets
Lindén, D., & Romeo, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.007 · Cited by 87
Tham, Y. K., Bernardo, B. C., Huynh, K., Ooi, J. Y. Y., Gao, X. M., Kiriazis, H., Giles, C., Meikle, P. J., & McMullen, J. R. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.017 · Cited by 85
PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
Cherubini, A., Casirati, E., Tomasi, M., & Valenti, L. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2018418 · Cited by 79 · cited 1×
“Genetic variants in HSD17B13 have been shown to protect against the development of MASH and conversely the PNPLA3 I148M variant has been shown to promote the development of MASH ( 32 , 48 – 53 ).”
Vatner, D. F., Goedeke, L., Camporez, J.-P. G., Lyu, K., Nasiri, A. R., Zhang, D., Bhanot, S., Murray, S. F., Still, C. D., Gerhard, G. S., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4579-1 · Cited by 76
Self-citationLuukkonen, P. K., Juuti, A., Sammalkorpi, H., Penttilä, A. K., Orešič, M., Hyötyläinen, T., Arola, J., Orho-Melander, M., & Yki-Järvinen, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.021 · Cited by 72
Zhou, L., Qiu, X., Meng, Z., Liu, T., Chen, Z., Zhang, P., Kuang, H., Pan, T., Lu, Y., Qi, L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk1866 · Cited by 70
Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH)
Min-DeBartolo, J. H., Schlerman, F. J., Akare, S., Wang, J., McMahon, J. B., Zhan, Y., Syed, J., He, W., Zhang, B., & Martinez, R. V. P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226854 · Cited by 69
Amangurbanova, M., Huang, D. Q., & Loomba, R. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17292 · Cited by 59
Camporez, J. P. G., Kanda, S., Petersen, M. C., Jornayvaz, F. R., Samuel, V. T., Bhanot, S., Petersen, K. F., Jurczak, M. J., & Shulman, G. I. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054080 · Cited by 58
Self-citationSugasawa, T., Ono, S., Yonamine, M., Fujita, S.-I., Matsumoto, Y., Aoki, K., Nakano, T., Tamai, S., Yoshida, Y., Kawakami, Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115851 · Cited by 55
Lysosomal cholesterol overload in macrophages promotes liver fibrosis in a mouse model of NASH
Itoh, M., Tamura, A., Kanai, S., Tanaka, M., Kanamori, Y., Shirakawa, I., Ito, A., Oka, Y., Hidaka, I., Takami, T., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220681 · Cited by 51
Su, W., Wu, S., Yang, Y., Guo, Y., Zhang, H., Su, J., Chen, L., Mao, Z., Lan, R., Cao, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34299-1 · Cited by 49
Kram, M. T. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i2.201 · Cited by 42
Advances in the genetics of nonalcoholic fatty liver disease
Ajmera, V. H., & Loomba, R. S. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000927 · Cited by 41
Galectin-3: therapeutic targeting in liver disease
Mackinnon, A. C., Tonev, D., Jacoby, B., Pinzani, M., & Slack, R. J. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2258280 · Cited by 38
Hu, P., Li, H., Sun, W., Wang, H., Yu, X., Qing, Y., Wang, Z., Zhu, M., Xu, J., Guo, Q., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.004 · Cited by 35
Statin use and liver-related prognosis among patients with MASLD
Yun, B., Park, H., Lee, J., Kim, B. K., & Yoon, J. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101313 · Cited by 35
Desjardins, E. M., Wu, J., Lavoie, D. C. T., Ahmadi, E., Townsend, L. K., Morrow, M. R., Wang, D., Tsakiridis, E. E., Batchuluun, B., Fayyazi, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101193 · Cited by 33 · cited 1×
“In addition recent studies have also demonstrated that bempedoic acid reduces the development of liver inflammation in mouse models of MASH ( 22 , 45 ).”
Männistö, V., Kamińska, D., Kärjä, V. J., Tiainen, M., de Mello, V. D., Hanhineva, K., Soininen, P., Ala‐Korpela, M., & Pihlajamäki, J. (2019) · Liver International · doi:10.1111/liv.14174 · Cited by 33
Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1 -mutated myelodysplasia
Mian, S. A., Philippe, C., Maniati, E., Protopapa, P., Bergot, T., Piganeau, M., Nemkov, T. G., Bella, D. D., Morales, V., Finch, A. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn5135 · Cited by 32
Sanjay, K. V., Vishwakarma, S., Zope, B. R., Mane, V. S., Mohire, S., & Dhakshinamoorthy, S. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100051 · Cited by 30
Gaspar, R. C., Lyu, K., Hubbard, B. T., Leitner, B. P., Luukkonen, P. K., Hirabara, S. M., Sakuma, I., Nasiri, A. R., Zhang, D., Kahn, M., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05838-8 · Cited by 29
Self-citationInherited Disorders of Coenzyme A Biosynthesis: Models, Mechanisms, and Treatments
Cavestro, C., Diodato, D., Tiranti, V., & Meo, I. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065951 · Cited by 28
Sakuma, I., Gaspar, R. C., Luukkonen, P. K., Kahn, M., Zhang, D., Zhang, X., Murray, S., Golla, J. P., Vatner, D. F., Samuel, V. T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2312666120 · Cited by 26
Self-citationLockhart, S. M., Mušo, M., Zvetkova, I., Lam, B., Ferrari, A., Schoenmakers, E., Duckett, K., Leslie, J., Collins, A., Romartínez-Alonso, B., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01126-4 · Cited by 24
Novo, E., Cappon, A., Villano, G., Quarta, S., Cannito, S., Bocca, C., Turato, C., Guido, M., Maggiora, M., Protopapa, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910526 · Cited by 21
Xu, S., Smothers, J. C., Rye, D., Endapally, S., Chen, H., Li, S., Liang, G., Kinnebrew, M., Rohatgi, R., Posner, B. A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318024121 · Cited by 19
SREBP1 regulates Lgals3 activation in response to cholesterol loading
Li, J., Shen, H., Owens, G. K., & Guo, L. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.05.028 · Cited by 16
Provera, A., Ramavath, N. N., Gadipudi, L. L., Gigliotti, C. L., Boggio, E. M., Vecchio, C., Stoppa, I., Rolla, R., Boldorini, R. L., Pirisi, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290391 · Cited by 13
Sakuma, I., Nagano, H., Hashimoto, N., Fujimoto, M., Nakayama, A., Fuchigami, T., Taki, Y., Matsuda, T., Akamine, H., Kono, S., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05160-y · Cited by 13
Self-citationBempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action
Roglans, N., Laguna, J. C., & Alegret, M. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000878 · Cited by 11
Johnson, S., Bao, H., McMahon, C., Chen, Y., Burr, S. D., Anderson, A. M., Madeyski-Bengtson, K., Lindén, D., Han, X., & Liu, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.30.553213 · Cited by 3
Research works printed but not linked: 1
- S. M. Johnson, PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein. Nat. Commun. 15, 4847 (2024). 38844467 PMC11156938 · DOI · Paper page
Cited by
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
Mechanisms and therapeutic insights into MASH-associated fibrosis
Zhu, Y., & Cai, B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.09.004 · Cited by 34
Pastena, F. D., Gautam, J., Lally, J., Fayyazi, R., Grasset, E., Bhattacharya, D., Fidelito, G., Ahmadi, E., Townsend, L. K., Batchuluun, B., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.015 · Cited by 27
Liu, Y., Wang, Y., Zhou, J., Li, H., Liu, C., Zhong, B., Liu, J., Liu, L., Zhang, L., & Sun, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1718799 · Cited by 17
Lipid metabolism and metabolites: emerging roles in systemic physiology and metabolic diseases
Xu, J., Lu, D., & Huang, X. (2026) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2026.01.006 · Cited by 18
Metadata
- Authors
- Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., Yimlamai, D., Perelis, M., Vatner, D. F., Petersen, K. F., Huttasch, M., Knebel, B., Kahl, S., Roden, M., Samuel, V. T., Tanaka, T., & Shulman, G. I.
- Affiliations
- Chiba University (JP)
- Yale University (US)
- Kazusa DNA Research Institute (JP)
- Ionis Pharmaceuticals (United States) (US)
- Deutsches Diabetes-Zentrum e.V. (DE)
- Düsseldorf University Hospital (DE)
- Veterans Health Administration (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Shulman, Gerald I.
- ORCID
- Sakuma, Ikki
- Gaspar, Rafael C.
- Nasiri, Ali R.
- Dufour, Sylvie
- Kahn, Mario
- LaMoia, Traci E.
- Guerra, Mateus T.
- Taki, Yuki
- Kawashima, Yusuke
- Yimlamai, Dean
- Perelis, Mark
- Vatner, Daniel F.
- Petersen, Kitt Falk
- Huttasch, Maximilian
- Knebel, Birgit
- Kahl, Sabine
- Roden, Michael
- Samuel, Varman T.
- Tanaka, Tomoaki
- Shulman, Gerald I.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2025-05
- Volume
- 122
- Issue
- 18
- Pages
- e2502978122-e2502978122
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC12067271
- OpenAlex
- W4409995331
- Cited by
- 46
- References
- 80
- Citations by year
- 2026: 35 · 2025: 11
- FWCI
- 31.66
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-10-01)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion)
- Funders
- Manpei Suzuki Diabetes Foundation (N/A)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (F31DK126362, P30 DK34989, R01 DK119968, R01 DK113984, P30 DK045735, R01 DK133143)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- nonalcoholic steatohepatitis, cholesterol, liver fibrosis, choline-deficient L-amino acid-defined diet, bempedoic acid, atorvastatin, antisense oligonucleotides, PNPLA3, HSD17B13, bioactive lipids, liver inflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.